Yasufumi Ohfume

Title: Yasufumi Ohfume: Innovator in Neuropharmacology

Introduction

Yasufumi Ohfume is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of neuropharmacology through his innovative research and development of novel compounds. His work focuses on the N-methyl-D-aspartate (NMDA) receptor, which plays a crucial role in the central nervous system.

Latest Patents

Yasufumi Ohfume holds a patent for a compound known as Carboxycyclopropylglycine. This compound, represented by the formula (1), has been identified as the most potent agonist for the NMDA receptor. The implications of this discovery are profound, as it opens avenues for developing glutamic acid receptor antagonists that may provide therapeutic benefits for conditions such as epilepsy, Huntington's chorea, Parkinsonism, and various neurodegenerative disorders. The patent also details a process for producing this compound and synthesizing four carboxycyclopropylglycine stereoisomers.

Career Highlights

Ohfume is associated with Suntory Limited, a company known for its commitment to innovation and research in various fields, including pharmaceuticals. His work has positioned him as a key figure in the development of new therapeutic agents that target critical neurological pathways.

Collaborations

Yasufumi Ohfume collaborates with notable colleagues, including Keiko Shimamoto and Haruhiko Shinozaki. Their combined expertise enhances the research efforts and contributes to the advancement of neuropharmacological studies.

Conclusion

Yasufumi Ohfume's contributions to the field of neuropharmacology through his patent on Carboxycyclopropylglycine exemplify the impact of innovative research on therapeutic development. His work continues to pave the way for advancements in treating neurological disorders.